Biogen Deferred Taxes decreased by 4.7% to $483.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 263.0%, from $133.20M to $483.50M. Over 5 years (FY 2020 to FY 2025), Deferred Taxes shows a downward trend with a -13.2% CAGR.
An increase suggests the company is deferring tax payments, which can improve current cash flow, while a decrease indicates the settlement of these deferred obligations.
This represents the amount of income taxes payable in future periods as a result of temporary differences between the ca...
Standard across all industries; levels are driven by capital expenditure cycles and depreciation methods.
other_deferred_income_tax_liabilities_net| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $918.90M | $774.70M | $694.50M | $571.20M | $480.60M | $328.90M | $334.70M | $251.30M | $143.90M | $728.10M | $641.80M | $658.10M | $590.60M | $882.40M | $190.50M | $133.20M | $118.30M | $358.10M | $507.60M | $483.50M |
| QoQ Change | — | -15.7% | -10.4% | -17.8% | -15.9% | -31.6% | +1.8% | -24.9% | -42.7% | +406.0% | -11.9% | +2.5% | -10.3% | +49.4% | -78.4% | -30.1% | -11.2% | +202.7% | +41.7% | -4.7% |
| YoY Change | — | — | — | — | -47.7% | -57.5% | -51.8% | -56.0% | -70.1% | +121.4% | +91.8% | +161.9% | +310.4% | +21.2% | -70.3% | -79.8% | -80.0% | -59.4% | +166.5% | +263.0% |